This is a really good article about Dr. Hoenderkamp's nightmare experience on Levo and her fears about the future of T3 on the NHS. Interestingly is the statement by Concordia at the end of the article who cite 'manufactory and regulatory approval' as a reason for the price hike. So why is T3 so cheap in Europe? Concordia has now resolved the manufacturing issues, two other manufacturers have invested, so prices are expected to 'drop significantly' in the future. Does that mean commercial competition is the driving factor here. If you also read the GP comments at the very end of the article, one doctor suggests that only Endo's can prescribe T3, which he thinks would solve the problem. GP's would have to refer. This would involve a huge amount of extra work for Endo's so I hope they would be well prepared and better informed. One GP ('Cobblers' - great name), suggests why the NHS can't import cheaper drugs from the EU.